Forgot your password?

Back to login

Pill in place of injection for diabetes
October 29, 2017, 3:29 pm

An injectable class of diabetes medication called glucagon-like peptide-1 (GLP-1), could be made available in a pill form, says a new study funded by Novo Nordisk, the Denmark-based multinational pharmaceutical company that makes the drug, called Oral Semaglutide.

Based on the results of a six-month long global phase 2 clinical trial of the pill, the researchers reported a significant drop in blood sugar levels among diabetic patients, with no significant increase in low blood sugar levels (hypoglycemia) compared to a placebo over six months.

The study included just over 1,100 people with type 2 diabetes recruited from 100 centers in 14 countries around the world. The volunteers' average age was 57. The average time they'd had type 2 diabetes was six years, and, on average, they were considered obese.

The study also found that people taking the highest dose of the pill lost a large amount of weight — around seven kilos — compared to a weight loss of fewer than 1.5 kilos for people on the inactive placebo pill.

The most common side effects caused by the pill were found to be mild to moderate digestive concerns that tended to go away with time. Nausea was less common in people who started on the lowest dose and then were given stronger doses.

Doctors say that Semaglutide could transform diabetes treatment as it has all the ingredients for an excellent medication and it could be very good for type 2 diabetes.

Share your views

"It is hard to fail, but it is worse never to have tried to succeed."

"Envy comes from wanting something that isn't yours. But grief comes from losing something you've already had."

Photo Gallery